Oculocutaneous albinism
| Oculocutaneous albinism | |
|---|---|
| Synonyms | OCA |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Hypopigmentation of the skin, hair, and eyes |
| Complications | Vision impairment, Skin cancer |
| Onset | Congenital |
| Duration | Lifelong |
| Types | OCA1, OCA2, OCA3, OCA4 |
| Causes | Genetic mutation |
| Risks | Increased risk of skin cancer |
| Diagnosis | Genetic testing, Ophthalmologic examination |
| Differential diagnosis | Hermansky–Pudlak syndrome, Chediak–Higashi syndrome |
| Prevention | None |
| Treatment | Sun protection, Vision aids |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | 1 in 20,000 |
| Deaths | N/A |
A group of genetic conditions affecting pigmentation in the skin, hair, and eyes
Oculocutaneous albinism (OCA) is a group of rare genetic disorders characterized by a reduction or complete lack of melanin pigment in the skin, hair, and eyes. This condition affects individuals of all ethnic backgrounds and is associated with vision problems and increased risk of skin damage due to sun exposure.
Types[edit]
Oculocutaneous albinism is classified into several types based on the specific genetic mutations involved. The most common types include:
OCA1[edit]
OCA1 is caused by mutations in the TYR gene, which encodes the enzyme tyrosinase. This enzyme is crucial for the production of melanin. OCA1 is further divided into two subtypes:
- OCA1A: Characterized by a complete absence of tyrosinase activity, resulting in no melanin production. Individuals with OCA1A have white hair, very pale skin, and light-colored eyes.
- OCA1B: Involves reduced tyrosinase activity, allowing for some melanin production. Individuals may have light blonde hair and slightly more pigmentation in the skin and eyes compared to OCA1A.
OCA2[edit]
OCA2 is the most common form of albinism worldwide and is caused by mutations in the OCA2 gene. This gene is involved in the transport of tyrosine, a precursor to melanin, into the melanosomes. Individuals with OCA2 typically have light skin and hair, but more pigmentation than those with OCA1.
OCA3[edit]
OCA3 is caused by mutations in the TYRP1 gene, which encodes the enzyme tyrosinase-related protein 1. This type is more common in individuals of African descent and results in reddish-brown skin, hair, and eye color.
OCA4[edit]
OCA4 is caused by mutations in the SLC45A2 gene, which is involved in melanin production. This type is more prevalent in certain populations, such as those of East Asian descent, and results in a phenotype similar to OCA2.
Symptoms[edit]
The primary symptoms of oculocutaneous albinism include:
- Hypopigmentation: Reduced pigmentation in the skin, hair, and eyes.
- Vision problems: Including nystagmus (involuntary eye movements), strabismus (misalignment of the eyes), photophobia (sensitivity to light), and reduced visual acuity.
- Increased risk of skin damage: Due to lack of melanin, individuals are more susceptible to sunburn and skin cancer.
Diagnosis[edit]
Diagnosis of oculocutaneous albinism is based on clinical evaluation, family history, and genetic testing. Eye examinations can reveal characteristic changes in the retina and optic nerve. Genetic testing can confirm the specific type of OCA by identifying mutations in the associated genes.
Management[edit]
There is no cure for oculocutaneous albinism, but management focuses on protecting the skin and eyes from sun damage and addressing vision problems. This includes:
- Sun protection: Using sunscreen, wearing protective clothing, and avoiding excessive sun exposure.
- Vision aids: Prescription glasses, contact lenses, and low vision aids can help improve visual function.
- Regular eye exams: To monitor and manage vision problems.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian